BackLiminal Biosciences Overview

Liminal Biosciences Current Assets

Liminal Biosciences's current assets is $26M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$25.64M
↓ 57.96% YoYΔ $-35.35M vs prior year quarter

Peer trimmed avg / median

Loading

Liminal Biosciences Current Assets History

Loading

Liminal Biosciences vs. peers: Current Assets Comparison

Loading

Liminal Biosciences Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Liminal Biosciences (LMNL) FAQ

Liminal Biosciences posts a current assets of $26M as of June 2023. That compares with $61M in the prior-year period — down 58.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Liminal Biosciences's current assets was $61M. The latest reading is $26M — a 58.0% year-over-year decrease (period ending June 2023). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Liminal Biosciences's financial statement story. At $26M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LMNL's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Liminal Biosciences's other metric pages and overview cover the third.

Judging Liminal Biosciences against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current assets easier to interpret. Start with $26M here, then scan peer and history charts to see if the gap is persistent.